Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Tidal Investments LLC

Tidal Investments LLC lowered its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 3.3% during the third quarter, HoldingsChannel reports. The institutional investor owned 21,827 shares of the biopharmaceutical company’s stock after selling 742 shares during the quarter. Tidal Investments LLC’s holdings in Agios Pharmaceuticals were worth $970,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at approximately $40,000. Mirae Asset Global Investments Co. Ltd. raised its position in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the period. CWM LLC lifted its stake in Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Agios Pharmaceuticals during the third quarter worth $146,000.

Insiders Place Their Bets

In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. This trade represents a 11.20 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.93% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AGIO. Raymond James restated an “outperform” rating and set a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Leerink Partners lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Royal Bank of Canada raised their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Finally, Scotiabank upped their price objective on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a research report on Monday, December 9th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $35.81 on Friday. The stock’s 50-day simple moving average is $49.94 and its 200-day simple moving average is $46.71. The firm has a market capitalization of $2.04 billion, a PE ratio of 3.15 and a beta of 0.80. Agios Pharmaceuticals, Inc. has a fifty-two week low of $20.96 and a fifty-two week high of $62.58.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.